- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Immunovia AB: Immunovia enters into top guarantee commitments for the upcoming rights issue | 79 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 28.08. | Immunovia Q2 2025 slides: PancreaSure launch plan unveiled amid stock decline | 3 | Investing.com | ||
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 28.08. | Immunovia-Aktie bricht nach Q2-Zahlen ein - trotz neuem Krebstest | 3 | Investing.com Deutsch | ||
| 28.08. | Immunovia AB: Immunovia Publishes Interim Report for January-June 2024 | 75 | GlobeNewswire (Europe) | April-June 2025Net sales, which for the quarter only included royalties, amounted to 90 KSEK (85).Operating loss was -20.1 MSEK, down from -23.9 MSEK in the second quarter of 2024. Net earnings were... ► Artikel lesen | |
| 27.08. | Immunovia AB: Immunovia carries out a rights issue of approximately SEK 100 million and secures bridge loans | 253 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 19.08. | Immunovia AB: Immunovia set to launch PancreaSure in the US on September 2nd, shares commercial strategy | 103 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.) the pancreatic cancer diagnostics company, today announced that the PancreaSure test is set to launch in the US on September 2nd. The company's initial focus will be... ► Artikel lesen | |
| 14.05. | Immunovia AB: Immunovia Publishes Interim Report for January-March 2025 | 205 | GlobeNewswire (Europe) | January-March 2025• Net sales, which for the quarter only included royalties, amounted to 139 KSEK (156).• Net earnings were -57.8 MSEK (-2.9), as a result of unrealized exchange rate effects due to... ► Artikel lesen | |
| 02.04. | IMMUNOVIA AB: Immunovia publishes the Annual Report for 2024 | 1 | Cision News | ||
| 01.04. | IMMUNOVIA AB: The exercise period for warrants series TO 3 begins today | 2 | Cision News | ||
| 27.03. | IMMUNOVIA AB: Immunovia announces determined exercise price for warrants series TO 3 | 2 | Cision News | ||
| 24.03. | Immunovia AB: Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test | 216 | PR Newswire | LUND, Sweden, March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results... ► Artikel lesen | |
| 24.03. | Immunovia AB: Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test | 190 | GlobeNewswire (Europe) | LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic... ► Artikel lesen | |
| 21.03. | IMMUNOVIA AB: Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study | 2 | Cision News | ||
| 19.03. | Immunovia AB: Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test | 177 | GlobeNewswire (Europe) | LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second clinical validation study of its next-generation... ► Artikel lesen | |
| 25.02. | Immunovia AB: Immunovia Publishes Full Year Report for 2024 | 230 | PR Newswire | LUND, Sweden, Feb. 25, 2025 /PRNewswire/ --
October- December 2024
Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155).
... ► Artikel lesen | |
| 31.01. | Change in number of shares and votes in Immunovia AB (publ) | 300 | PR Newswire | LUND, Sweden, Jan. 31, 2025 /PRNewswire/ -- During January 2025, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due exercise of warrants of series... ► Artikel lesen | |
| 20.01. | Immunovia AB announces outcome of exercise of warrants series TO 2 | 374 | PR Newswire | LUND, Sweden, Jan. 20, 2025 /PRNewswire/ -- The exercise period for warrants series TO 2 (the "Warrant Programme") in Immunovia AB (publ) ("Immunovia" or the "Company") ended on 16 January... ► Artikel lesen | |
| 08.01. | Immunovia AB (Publ) presents Nomination Committee | 296 | PR Newswire | LUND, Sweden, Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee.... ► Artikel lesen | |
| 02.01. | The exercise period for warrants of series TO 2 beings today: Immunovia AB | 392 | PR Newswire | LUND, Sweden, Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2... ► Artikel lesen | |
| 28.12.24 | Immunovia AB: Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme | 914 | PR Newswire | LUND, Sweden, Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HIMS & HERS HEALTH | 40,990 | +0,37 % | Hims & Hers Stock Jumps On Long-Awaited Foray Into Testosterone | ||
| BECTON DICKINSON | 160,45 | -0,43 % | Dividendenbekanntmachungen (08.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALPHABET INC CDR CA02080K1049 0,0341 CAD 0,0211 EUR ALPHABET INC CL A US02079K3059 0,21 USD 0,1791 EUR ALPHABET INC CL C US02079K1079 0... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting | -- Special Meeting to be held on September 26, 2025 --
SAN DIEGO, Sept. 9, 2025 /PRNewswire/ -- In an update to stockholders today, Evofem Biosciences, Inc.... ► Artikel lesen | |
| RYMAN HEALTHCARE | 1,213 | -2,49 % | RYMAN HEALTHCARE LIMITED: Capital Change Notice - Performance Share Rights | ||
| SOLENO THERAPEUTICS | 51,55 | +0,49 % | Soleno-Aktie bricht nach Meldung über Todesfall ein - Baird hält an Kaufempfehlung fest | ||
| NIAGEN BIOSCIENCE | 7,850 | -4,27 % | Niagen Bioscience, Inc: Niagen Bioscience to Participate at the Roth 15th Annual London Conference | Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces... ► Artikel lesen | |
| SIENNA SENIOR LIVING | 11,100 | 0,00 % | Sienna Senior Living Announces the Opening of Its Long-Term Care Community in North Bay and Retirement Community in Brantford, Ontario | ||
| MICROPORT SCIENTIFIC | 1,490 | -1,97 % | Shanghai MicroPort MedBot stock upgraded by JPMorgan on strong growth | ||
| EXTENDICARE | 8,050 | 0,00 % | Dividendenbekanntmachungen (29.08.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACNB CORPORATION US0008681092 0,34 USD 0,2911 EUR ADVANCED DRAINAGE SYSTEMS INC US00790R1041 0,18 USD 0,1541 EUR AEBI SCHMIDT HOLDING... ► Artikel lesen | |
| VERADIGM | 3,200 | 0,00 % | Veradigm extends the existing stockholder rights plan | ||
| NATIONAL HEALTHCARE CORPORATION | 96,00 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 28.08.2025 | The following instruments on XETRA do have their first trading 28.08.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 28.08.2025
Aktien
1 US6359061008 National Healthcare... ► Artikel lesen | |
| UNIPHAR | 3,990 | +0,88 % | Santhera Pharmaceuticals Holding AG: Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE (Vamorolone) in five GCC (Gulf Cooperation Council) Countries | Pratteln, Switzerland, 19 August, 2025 - Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the... ► Artikel lesen | |
| HANGZHOU TIGERMED CONSULTING | 5,550 | 0,00 % | TIGERMED (03347): FORM OF PROXY FOR THE 2025 FIRST EXTRAORDINARY GENERAL MEETING TO BE HELD ON MONDAY, SEPTEMBER 29, 2025 | ||
| AESTHETIC MEDICAL INTERNATIONAL | 0,120 | 0,00 % | Aesthetic Medical International Holdings Group Ltd - 6-K, Report of foreign issuer | ||
| SIEMENS HEALTHINEERS | 48,280 | +2,20 % | Siemens Healthineers: Die Langeweile setzt sich fort! |
IMMUNOVIA AB gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,079 Euro und damit -0,38 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.